Latanoprost and Gabapentin drug interactions - from FDA reports

Summary

Drug interactions are reported among people who take Latanoprost and Gabapentin together. This study is created by eHealthMe based on reports of 645 people who take Latanoprost and Gabapentin from FDA, and is updated regularly.



What's eHealthMe?

eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.

eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.

The information that eHealthMe collects includes:

  • Side effects (including severity and how people recover from them)
  • Associated conditions or symptoms
  • Drug effectiveness
  • Demographic data regarding drug use

How the study uses the data?

The study is based on latanoprost and gabapentin (the active ingredients of Latanoprost and Gabapentin, respectively), and Latanoprost and Gabapentin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

What is Latanoprost?

Latanoprost has active ingredients of latanoprost. It is often used in glaucoma. (latest outcomes from Latanoprost 11,517 users)

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in neuralgia. (latest outcomes from Gabapentin 147,960 users)

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.


On Mar, 18, 2019

645 people who take Latanoprost, Gabapentin are studied.


Number of reports submitted per year:

Latanoprost and Gabapentin drug interactions.

Most common drug interactions over time *:

< 1 month:
  1. Nasopharyngitis (inflammation of the nasopharynx)
  2. Plasma cell myeloma (cancer that begins in plasma cells)
  3. Somnolence (a state of near-sleep, a strong desire for sleep)
  4. Asthenia (weakness)
  5. Condition
  6. Disease recurrence
  7. Drug effect decreased
  8. Drug ineffective
  9. Dry mouth
  10. Fatigue (feeling of tiredness)
1 - 6 months:
  1. Depression
  2. Dizziness
  3. Hyperhidrosis (abnormally increased sweating)
  4. Sleep disorder
  5. Suicidal ideation
  6. Disorientation (disability in which the senses of time, direction, and recognition of people and places)
  7. Hunger
  8. Myalgia (muscle pain)
  9. Sensory disturbance (sense disturbance)
  10. Application site dermatitis
6 - 12 months:
  1. Condition
  2. Drug ineffective
  3. Hypoaesthesia (reduced sense of touch or sensation)
  4. Nerve compression
  5. Peripheral swelling
  6. Somnolence (a state of near-sleep, a strong desire for sleep)
  7. Weight decreased
  8. Cervical radiculopathy (disturbance of nerve function that causes pain in the upper body)
  9. Nerve injury
  10. Therapeutic response decreased (less preventive response)
1 - 2 years:
  1. Cold sweat
  2. Hypoacusis (loss of hearing)
  3. Muscle spasms (muscle contraction)
  4. Nasopharyngitis (inflammation of the nasopharynx)
  5. Nausea (feeling of having an urge to vomit)
  6. Tremor (trembling or shaking movements in one or more parts of your body)
  7. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  8. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  9. Pain in extremity
  10. Supraventricular tachycardia (rapid heart rhythm originating at or above the atrioventricular node)
2 - 5 years:
  1. Chronic kidney disease
  2. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  3. Renal failure (kidney dysfunction)
5 - 10 years:
  1. Blood creatinine increased
  2. Cardiac arrest
  3. Death
  4. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)
  5. Respiratory failure (inadequate gas exchange by the respiratory system)
10+ years:

n/a

not specified:
  1. Arthralgia (joint pain)
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Vomiting
  4. Constipation
  5. Gait disturbance
  6. Muscular weakness (muscle weakness)
  7. Neuropathy peripheral (surface nerve damage)
  8. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  9. Asthenia (weakness)
  10. Back pain

Most common drug interactions by gender *:

female:
  1. Neuropathy peripheral (surface nerve damage)
  2. Vomiting
  3. Arthralgia (joint pain)
  4. Condition
  5. Pain in extremity
  6. Peripheral swelling
  7. Constipation
  8. Malaise (a feeling of general discomfort or uneasiness)
  9. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  10. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
male:
  1. Diarrhoea
  2. Confusional state
  3. Back pain
  4. Fall
  5. Pneumonia
  6. Abdominal discomfort
  7. Arthralgia (joint pain)
  8. Fatigue (feeling of tiredness)
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Nausea (feeling of having an urge to vomit)

Most common drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:
  1. Decreased appetite
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Migraine (headache)
  4. Pyrexia (fever)
  5. Vertigo
  6. Viral infection
  7. Ill-defined disorder
  8. Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
20-29:

n/a

30-39:
  1. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  2. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  4. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  5. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  6. Dizziness
  7. Neuropathy peripheral (surface nerve damage)
  8. Purpura senile (skin condition in which areas of the skin develop a purplish or reddish-brown appearance due to bleeding of small blood vessels underneath)
  9. Renal failure (kidney dysfunction)
  10. Resorption bone increased
40-49:
  1. Nerve compression
  2. Peripheral swelling
  3. Condition
  4. Hypoaesthesia (reduced sense of touch or sensation)
  5. Somnolence (a state of near-sleep, a strong desire for sleep)
  6. Weight decreased
  7. Cervical radiculopathy (disturbance of nerve function that causes pain in the upper body)
  8. Drug ineffective
  9. Nerve injury
  10. Therapeutic response decreased (less preventive response)
50-59:
  1. Influenza
  2. Nasopharyngitis (inflammation of the nasopharynx)
  3. Nausea (feeling of having an urge to vomit)
  4. Arthralgia (joint pain)
  5. Back pain
  6. Chest pain
  7. Dehydration (dryness resulting from the removal of water)
  8. Dizziness
  9. Dry mouth
  10. Malaise (a feeling of general discomfort or uneasiness)
60+:
  1. Nausea (feeling of having an urge to vomit)
  2. Headache (pain in head)
  3. Pneumonia
  4. Malaise (a feeling of general discomfort or uneasiness)
  5. Vomiting
  6. Weight decreased
  7. Constipation
  8. Pyrexia (fever)
  9. Abdominal pain upper
  10. Asthenia (weakness)

* Approximation only. Some reports may have incomplete information.

Do you take Latanoprost and Gabapentin?


You are not alone:




Related publications that referenced our studies


Results from eHealthMe (non-FDA) reports of taking Latanoprost and Gabapentin together

Drug effectiveness (drug is found to be effective) over time *:
Latanoprost:
  • < 1 month: 0.0% (0 of 0 people)
  • 1 - 6 months: 100% (1 of 1 people)
  • 6 - 12 months: 0.0% (0 of 0 people)
  • 1 - 2 years: 100% (1 of 1 people)
  • 2 - 5 years: 0.0% (0 of 1 people)
  • 5 - 10 years: 0.0% (0 of 0 people)
  • 10+ years: 0.0% (0 of 0 people)
  • not specified: 0.0% (0 of 0 people)
Gabapentin:
  • < 1 month: 0.0% (0 of 0 people)
  • 1 - 6 months: 0.0% (0 of 0 people)
  • 6 - 12 months: 0.0% (0 of 0 people)
  • 1 - 2 years: 0.0% (0 of 0 people)
  • 2 - 5 years: 0.0% (0 of 2 people)
  • 5 - 10 years: 0.0% (0 of 0 people)
  • 10+ years: 0.0% (0 of 0 people)
  • not specified: 0.0% (0 of 1 people)
Drug effectiveness (drug is found to be effective) by gender *:
Latanoprost:
  • female: 100% (2 of 2 people)
  • male: 0.0% (0 of 1 people)
Gabapentin:
  • female: 0.0% (0 of 2 people)
  • male: 0.0% (0 of 1 people)
Drug effectiveness (drug is found to be effective) by age *:
Latanoprost:
  • 0-1: 0.0% (0 of 0 people)
  • 2-9: 0.0% (0 of 0 people)
  • 10-19: 0.0% (0 of 0 people)
  • 20-29: 0.0% (0 of 0 people)
  • 30-39: 0.0% (0 of 0 people)
  • 40-49: 0.0% (0 of 0 people)
  • 50-59: 0.0% (0 of 0 people)
  • 60+: 66.0% (2 of 3 people)
Gabapentin:
  • 0-1: 0.0% (0 of 0 people)
  • 2-9: 0.0% (0 of 0 people)
  • 10-19: 0.0% (0 of 0 people)
  • 20-29: 0.0% (0 of 0 people)
  • 30-39: 0.0% (0 of 0 people)
  • 40-49: 0.0% (0 of 0 people)
  • 50-59: 0.0% (0 of 0 people)
  • 60+: 0.0% (0 of 3 people)
Race of the people *:
  • African American, Non-Hispanic: 0.0 %
  • American Indian/Alaska Native: 0.0 %
  • Asian: 0.0 %
  • Hispanic: 0.0 %
  • Native Hawaiians/Pacific Islanders: 0.0 %
  • Two or more races: 0.0 %
  • White, Non-Hispanic: 100 %

* Approximation only.


Related studies

Browse interactions by gender and age

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+


Interactions between Latanoprost and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Interactions between Gabapentin and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Browse all drug interactions of Latanoprost and Gabapentin
a b c d e f g h i j k l m n o p q r s t u v w x y z

What would happen?

Predict new side effects and undetected conditions when you take Latanoprost and Gabapentin (37,436 reports studied)



FDA reports used in this study


Recent updates

Recent general studies
Recent personal studies


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.